After washing, HSG cells were incubated with the second antibodies: fluorescein isothiocyanate (FITC)-conjugated rabbit anti-goat IgG antibodies (IgG; MP Biomedicals, Irvine, CA, USA). Stained HSG cells were observed by fluorescence microscope. HSG cells (15 000 cells/well) were precultured in 96-well plates for fluorescence assays at 37°C for 48 h. Then, the cells were preincubated with IgG fractions separated from sera of anti-M3R antibodies positive for five SS patients,

anti-M3R antibodies negative for one SS patient, and HC by using protein G column (1·0 mg/ml) for 12 h. The referral of the anti-M3R antibodies selleck compound positive or negative sera was on the basis of our ELISA results. IgG was washed off and the HSG cells were loaded with Fluo-3, which was a fluorescence

probe for calcium, for 1 h. Fluo-3 was washed off, and then the HSG cells were analysed. For the Ca2+ influx assay, the HSG cells were stimulated with cevimeline hydrochloride, which was a M3R specific agonist at a final concentration Bortezomib of 20 mM. Changes in intracellular calcium concentrations [(Ca2+)i] in HSG cells were measured by fluorescence plate reader. Maximum changes of (Ca2+)i [peak (Ca2+)i – baseline (Ca2+)i] in IgG from SS patients or without IgG were shown as ratiometric data compared to maximum change of (Ca2+)i in HC [2]. Differences between groups were examined for statistical significance PRKD3 using the Mann–Whitney U-test, while differences in frequencies were

analysed by Fisher’s exact probability test. A P-value less than 0·05 was considered as the statistically significant difference. The average age of SS patients was 53·1 ± 13·2 years, that of HC was 33·1 ± 8·7 years (P < 0·05, Mann–Whitney U-test). All 42 SS patients were female, 22 of HC female and 20 of HC male. Among 27 patients with secondary SS, 11 were complicated with rheumatoid arthritis (RA), 11 with systemic lupus erythematosus (SLE), two with mixed connective tissue disease (MCTD) and three with other autoimmune diseases. Anti-M3R antibodies were really specific for each M3R peptide, because the binding activities of sera from SS patients were dose-dependent and were not in the control sera from healthy subjects. Furthermore, sera from anti-M3R antibodies positive SS did not recognize the peptide corresponding to the sequences of the third extracellular loop of human-M5R (Fig. 1a). Antibodies to the N-terminal region were detected in 42·9% (18 of 42) of SS patients but in only 4·8% (two of 42) of the control (P < 0·05, Fisher’s exact probability test). Antibodies to the first extracellular loop were detected in 47·6% (20 of 42) of SS and 7·1% (three of 42) of the control (P < 0·05, Fisher’s exact probability test). Antibodies to the second extracellular loop were detected in 54·8% (23 of 42) of SS and 2·4% (one of 42) of the control (P < 0·05, Fisher’s exact probability test).